: Sensitivity analyses for severe exacerbations (n = trials). All forest plot show rate ratios and their 95% credible intervals (95%CI), median ranks (95%CI), compared to low dose inhaled corticosteroids. .113 *For analysis purposes, studies were classified as having overall low risk of bias if more than 50% of the individual items were scored as low risk of bias, while according the Cochrane Handbook a low risk of bias should be assigned when all domains are scored as low. S2F complete analysis severe exacerbations excluding trials without double-blinding n=57 ; τ2=0.102 n=44 ; τ2=0.129 COMBI = combined ICS and LABA in a single inhaler; COMBI AMD = COMBI in an adjustable maintenance dose; COMBI FIX = COMBI in a fixed daily dose; COMBI MAR = COMBI as maintenance and reliever therapy; ICS (H) = inhaled corticosteroids (H=high dose ICS); LABA = long-acting betaagonists; LTRA = leukotriene receptor antagonist; SABA = short -acting beta-agonists. Best Practice is an open label comparator in which practitioners are free to choose therapy at their own discretion but are encouraged to treat patients according to current treatment guidelines.
